Actively Recruiting
Study of Donor-Derived CD7 CAR-T Cell Therapy Followed by Allogeneic Stem Cell Transplantation for Severe Aplastic Anemia
Led by Zhejiang University · Updated on 2024-10-09
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of CD7 CAR-T cell therapy followed by allogeneic hematopoietic stem cell transplantation allo-HSCT for patients with severe aplastic anemia. This early phase 1, open-label study aims to understand the dose-limiting toxicities and adverse events related to this treatment approach, which is designed for patients who are not suitable or unwilling to undergo traditional stem cell transplantation. The trial is conducted at a single center and sponsored by Zhejiang University. Participants will receive CD7 CAR-T cells as a novel treatment, followed by allo-HSCT as a bridging therapy. The study focuses on patients with severe aplastic anemia meeting specific diagnostic criteria and having suitable donors. The treatment and follow-up periods include monitoring for toxicities up to 28 days after treatment and adverse events up to two years post-treatment. Secondary goals include evaluating transplant success, blood cell recovery times, disease-free survival, and overall survival. Throughout the study, participants will undergo various assessments including blood tests, echocardiograms, and evaluations of organ function. Researchers will track treatment-emergent adverse events, transplant implantation success, and survival outcomes over a two-year period. Patients must meet performance status and organ function requirements and agree to contraception use if of childbearing potential. Participation includes regular monitoring and safety follow-up to evaluate the therapys impact and safety profile.
CONDITIONS
Brief Title
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
Research Team
H
He Z Huang, MD
Y
Yongxian Hu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here